Targeting THBS1 to Alleviate Oxidative Stress in PCOS: Insights from LSKL Intervention

Study Background and Research Question

Polycystic ovary syndrome (PCOS) is a multifaceted endocrine disorder, with a global prevalence estimated between 5% and 18%. It is characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology, but its impact extends beyond reproductive health, encompassing metabolic comorbidities such as obesity, type 2 diabetes mellitus, and cardiovascular diseases. Recent evidence highlights the involvement of chronic low-grade inflammation and oxidative stress in PCOS pathogenesis, linking abnormal ovarian angiogenesis and extracellular matrix (ECM) remodeling to the disease’s progression. Elevated levels of thrombospondin-1 (THBS1), a multifunctional ECM glycoprotein, have been associated with these pathological changes, but the potential for targeted intervention remained unclear.

The study by Zhang et al. (Life Sciences 386, 2026) addresses whether inhibiting THBS1 with the tetrapeptide Leu-Ser-Lys-Leu-NH2 (LSKL) can mitigate the oxidative stress and apoptosis induced by dehydroepiandrosterone (DHEA) in rat granulosa cells (GCs) and PCOS animal models, and explores the role of the PI3K/AKT signaling pathway in mediating these effects.

Key Innovation from the Reference Study

The central innovation lies in mechanistically dissecting how LSKL, as a selective inhibitor of THBS1, interrupts the pathological signaling underlying PCOS. By employing both in vitro and in vivo models, the study demonstrates that LSKL not only binds THBS1 with high affinity (confirmed by molecular docking) but also restores ovarian function by reducing oxidative damage and cell death. Importantly, the study pinpoints activation of the PI3K/AKT pathway as a critical downstream effector, providing molecular clarity on how THBS1 inhibition translates to improved cellular and tissue outcomes in the context of PCOS-related oxidative stress.

Methods and Experimental Design Insights

The research employed a well-established DHEA-induced PCOS model in rats, alongside primary granulosa cell cultures exposed to DHEA to induce apoptosis and oxidative stress. LSKL was administered to both models following PCOS induction. The following experimental approaches were key:

• Molecular docking to verify the high-affinity interaction between LSKL and THBS1.
• Cell viability and apoptosis assays in GCs, utilizing CCK8 and Annexin V/PI flow cytometry.
• ROS quantification in granulosa cells by flow cytometry, permitting sensitive detection of intracellular reactive oxygen species.
• In vivo evaluation of estrous cycles, ovarian histopathology, and serum hormone levels (LH, FSH, testosterone, estradiol) in rats.
• Western blotting and immunohistochemistry to assess PI3K/AKT pathway activation and expression of apoptosis-related proteins in ovarian tissue.

Notably, the detection of oxidative stress relied on established cell-permeable fluorogenic probes, enabling quantification of ROS at the single-cell level, which is critical for dissecting redox-dependent cellular responses in reproductive tissues.

Protocol Parameters

• DHEA induction: 21-day administration to rats or granulosa cells to establish PCOS phenotype and induce oxidative stress.
• LSKL treatment: Administered after PCOS induction; precise concentration and duration detailed in the original paper, with molecular docking confirming THBS1 binding.
• Flow cytometry ROS assay: Used to measure intracellular ROS in GCs; protocols typically include incubation with a ROS-sensitive probe and fluorescence quantification.
• CCK8 cell viability assay: Applied to assess the cytoprotective effects of LSKL on DHEA-injured cells.
• In vivo outcome measures: Body weight, estrous cycle staging, ovarian morphology, and hormone profiling post-treatment.

Core Findings and Why They Matter

Zhang et al. (2026) report several pivotal outcomes:

• LSKL demonstrated high-affinity binding to THBS1, as predicted by molecular docking, confirming its role as a direct THBS1 inhibitor.
• In vitro, LSKL reduced DHEA-induced ROS accumulation and apoptosis in granulosa cells, while enhancing cell viability.
• LSKL treatment restored normal estrous cycling, reduced cystic ovarian morphology, normalized serum hormone levels, and suppressed apoptosis in PCOS rats.
• Activation of the PI3K/AKT pathway was observed in both granulosa cells and ovarian tissue following LSKL administration, supporting a mechanistic link between THBS1 inhibition and downstream prosurvival signaling.

These findings underscore the therapeutic potential of targeting the THBS1/PI3K/AKT axis in diseases characterized by oxidative stress and inflammatory tissue remodeling. The study positions THBS1 as a viable molecular target for PCOS and highlights the value of redox-sensitive assays in evaluating intervention efficacy.

Comparison with Existing Internal Articles

Several internal resources reinforce the methodological and mechanistic significance of this study. For instance, the internal article "LSKL Attenuates PCOS-Related Oxidative Stress via THBS1/PI3K/AKT" provides further context for LSKL's role in modulating ovarian redox balance and PI3K/AKT signaling, closely aligning with the reference study’s conclusions. In parallel, articles such as "2,7-Dichlorodihydrofluorescein Diacetate for ROS Detection Workflows" and "2,7-Dichlorodihydrofluorescein Diacetate in Inflammation Research" detail advanced methods for ROS quantification, including fluorescence microscopy and flow cytometry, which underpin the experimental strategies used by Zhang et al. The referenced paper’s application of flow cytometry-based ROS assays is consistent with these established workflows, highlighting the translational utility of sensitive ROS probes in reproductive and inflammatory disease research.

Limitations and Transferability

While the study offers robust mechanistic insights, several limitations merit consideration. The PCOS model is induced by DHEA administration, which, while widely accepted, may not capture the full complexity of human PCOS etiology. The translation of findings from rodent models and in vitro granulosa cells to clinical settings requires further validation. Additionally, while the PI3K/AKT pathway is implicated as a mediator of LSKL’s protective effects, other downstream or parallel signaling routes may contribute to the observed outcomes but were not exhaustively explored. Finally, the specificity and quantitative accuracy of ROS detection methods are subject to known artifacts; thus, careful experimental controls and probe selection remain essential for reliable interpretation.

Research Support Resources

To replicate or extend ROS detection workflows described in this study, researchers can employ 2,7-Dichlorodihydrofluorescein diacetate (DCFH-DA, SKU C3890), a cell-permeable fluorogenic probe widely validated for intracellular ROS quantification using fluorescence microscopy, flow cytometry, and plate-based assays. According to the product information, DCFH-DA offers high sensitivity for oxidative stress detection in live-cell models, but experimental design should include appropriate controls to account for probe specificity and potential artifacts. Adoption of validated reagent workflows can facilitate robust, reproducible analysis of redox homeostasis and signaling events in both reproductive and inflammatory disease contexts. For further methodological guidance, related internal articles provide advanced troubleshooting strategies and cross-disease assay recommendations.